INInsmed INSM · NASDAQ
$95.29 -1.02% (-$0.98)
- Market cap
- $20.8B
- Enterprise value
- $20.8B
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 18.3x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -49.2%
- Gross margin
- 83.3%
- Net margin
- -76.9%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 0.82
- Free float
- 98.5%
About the company
Insmed Incorporated is an American biotechnology company focused on the development and commercialization of innovative therapies for patients suffering from rare and serious diseases. The company specializes in the treatment of lung diseases, particularly pulmonary hypertension and rare pulmonary infections, using advanced biologic and pharmaceutical products. Insmed is known for its work to improve the quality of life for patients who have no effective treatment options and focuses on developing new drugs for diseases that remain insufficiently treated.
Sector
Healthcare
Industry
Biotechnology
CEO
William H. Lewis
Employees
1,664
Headquarters
Bridgewater
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number